A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
ALX Oncology Inc.
NiKang Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
AstraZeneca
Eli Lilly and Company
Pliant Therapeutics, Inc.
Samsung Medical Center
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Compass Therapeutics
Hoosier Cancer Research Network
Eli Lilly and Company
Kivu Bioscience Inc.
Achieve Life Sciences
BicycleTx Limited
Astellas Pharma Inc
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Eli Lilly and Company
7 Hills Pharma, LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Plexium, Inc.
Deciphera Pharmaceuticals, LLC
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
USWM, LLC (dba US WorldMeds)
AstraZeneca
Actuate Therapeutics Inc.
Conjupro Biotherapeutics, Inc.
NRG Oncology
Alterome Therapeutics, Inc.
IDEAYA Biosciences
Pfizer
Incyte Corporation
Aulos Bioscience, Inc.
Assistance Publique - Hôpitaux de Paris
Memorial Sloan Kettering Cancer Center
Mirati Therapeutics Inc.
Aptamer Sciences, Inc.
National Institutes of Health Clinical Center (CC)
AstraZeneca
National Cancer Institute (NCI)
GlaxoSmithKline
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)